Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

OBJECTIVE: To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)/biologic (bDMARD...

Descripción completa

Detalles Bibliográficos
Autores principales: Fautrel, B, Zhu, B, Taylor, P C, van de Laar, M, Emery, P, De Leonardis, F, Kannowski, C L, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299519/
https://www.ncbi.nlm.nih.gov/pubmed/32371431
http://dx.doi.org/10.1136/rmdopen-2019-001131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299519/
https://www.ncbi.nlm.nih.gov/pubmed/32371431
http://dx.doi.org/10.1136/rmdopen-2019-001131

Ejemplares similares